BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8832021)

  • 1. Lymphocytosis of donor origin in cerebrospinal fluid, and marrow aplasia after donor leukocyte infusion for EBV-lymphoproliferative disease.
    Gharpure V; Rubin L; Amlin J; Emanuel D; Schroeder W; Davidson A; Hromas R; Cornetta K
    Bone Marrow Transplant; 1996 Jul; 18(1):221-4. PubMed ID: 8832021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.
    Papadopoulos EB; Ladanyi M; Emanuel D; Mackinnon S; Boulad F; Carabasi MH; Castro-Malaspina H; Childs BH; Gillio AP; Small TN
    N Engl J Med; 1994 Apr; 330(17):1185-91. PubMed ID: 8093146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response?
    Mackinnon S; Papadopoulos EB; Carabasi MH; Reich L; Collins NH; O'Reilly RJ
    Bone Marrow Transplant; 1995 Apr; 15(4):591-4. PubMed ID: 7655386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation.
    Chuhjo T; Yachie A; Kanegane H; Kimura H; Shiobara S; Nakao S
    Am J Hematol; 2003 Apr; 72(4):255-8. PubMed ID: 12666136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant.
    Porter DL; Orloff GJ; Antin JH
    Transplant Sci; 1994 Sep; 4(1):12-4; discussion 14-6. PubMed ID: 7804691
    [No Abstract]   [Full Text] [Related]  

  • 7. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Successful donor lymphocyte infusion for Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation from an HLA 1-locus-mismatched sibling donor in a patient with acute lymphocytic leukemia].
    Yago K; Itoh M; Shimada H
    Rinsho Ketsueki; 2001 Nov; 42(11):1105-10. PubMed ID: 11808079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia.
    Mavroudis DA; Read EJ; Molldrem J; Raptis A; Plante M; Carter CS; Phang S; Dunbar CE; Barrett AJ
    Bone Marrow Transplant; 1998 Mar; 21(5):431-40. PubMed ID: 9535034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful donor leukocyte infusion for chronic myeloid leukemia relapsing in accelerated phase after T cell-replete unrelated marrow transplantation.
    Grigg A; Szer J
    Bone Marrow Transplant; 1996 Sep; 18(3):647-8. PubMed ID: 8879633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
    Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
    Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor lymphocyte transfusion for the treatment of Epstein-Barr virus-associated lymphoproliferative disorder of the brain.
    Nagafuji K; Eto T; Hayashi S; Oshima K; Maeda Y; Gondo H; Inamura T; Niho Y
    Bone Marrow Transplant; 1998 Jun; 21(11):1155-8. PubMed ID: 9645581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Philadelphia chromosome positive acute lymphoblastic leukemia of donor origin after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase.
    Saito Y; Uzuka Y; Sakai N; Suzuki S; Toyota T
    Bone Marrow Transplant; 2000 Jun; 25(11):1209-11. PubMed ID: 10849535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
    Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
    Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia.
    Keil F; Haas OA; Fritsch G; Kalhs P; Lechner K; Mannhalter C; Reiter E; Niederwieser D; Hoecker P; Greinix HT
    Blood; 1997 May; 89(9):3113-7. PubMed ID: 9129013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal herpesvirus 6 encephalitis after unrelated bone marrow transplant.
    Bosi A; Zazzi M; Amantini A; Cellerini M; Vannucchi AM; De Milito A; Guidi S; Saccardi R; Lombardini L; Laszlo D; Rossi Ferrini P
    Bone Marrow Transplant; 1998 Aug; 22(3):285-8. PubMed ID: 9720744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
    Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
    Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell large granular lymphocyte leukemia of donor origin after allogeneic bone marrow transplantation.
    Au WY; Lam CC; Lie AK; Pang A; Kwong YL
    Am J Clin Pathol; 2003 Oct; 120(4):626-30. PubMed ID: 14560574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
    Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T
    Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.